Janux Therapeutics’ (JANX) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Janux Therapeutics (NASDAQ:JANX) in a research report report published on Thursday morning,Benzinga reports. The brokerage currently has a $63.00 price objective on the stock.

Other research analysts have also recently issued reports about the company. UBS Group assumed coverage on Janux Therapeutics in a report on Thursday, October 24th. They set a “buy” rating and a $69.00 target price on the stock. Cantor Fitzgerald restated an “overweight” rating and issued a $100.00 target price on shares of Janux Therapeutics in a report on Thursday. Scotiabank lowered their price target on shares of Janux Therapeutics from $47.00 to $42.00 and set a “sector perform” rating on the stock in a research report on Friday, August 9th. Stifel Nicolaus initiated coverage on shares of Janux Therapeutics in a research note on Friday, September 6th. They set a “buy” rating and a $70.00 target price on the stock. Finally, Wedbush reissued an “outperform” rating and issued a $74.00 price target on shares of Janux Therapeutics in a research note on Thursday, August 8th. One investment analyst has rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat, Janux Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $66.44.

Janux Therapeutics Stock Performance

Shares of JANX traded up $0.46 during trading hours on Thursday, hitting $54.67. 569,743 shares of the stock were exchanged, compared to its average volume of 712,373. The stock’s 50-day moving average price is $48.88 and its two-hundred day moving average price is $46.35. Janux Therapeutics has a 12-month low of $5.65 and a 12-month high of $65.60. The company has a market cap of $2.85 billion, a price-to-earnings ratio of -46.33 and a beta of 3.52.

Janux Therapeutics (NASDAQ:JANX) last issued its earnings results on Wednesday, November 6th. The company reported ($0.51) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.18). The business had revenue of $0.44 million during the quarter, compared to analyst estimates of $1.50 million. Janux Therapeutics had a negative net margin of 291.17% and a negative return on equity of 8.78%. The company’s revenue for the quarter was down 82.6% compared to the same quarter last year. On average, research analysts expect that Janux Therapeutics will post -1.18 earnings per share for the current year.

Insider Transactions at Janux Therapeutics

In related news, CEO David Alan Campbell sold 25,000 shares of Janux Therapeutics stock in a transaction that occurred on Monday, October 28th. The shares were sold at an average price of $53.54, for a total value of $1,338,500.00. Following the completion of the transaction, the chief executive officer now owns 282,054 shares in the company, valued at approximately $15,101,171.16. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In related news, major shareholder Ventures Xi L.P. Avalon sold 2,182 shares of Janux Therapeutics stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $42.33, for a total value of $92,364.06. Following the completion of the transaction, the insider now owns 7,000 shares in the company, valued at $296,310. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO David Alan Campbell sold 25,000 shares of the stock in a transaction that occurred on Monday, October 28th. The shares were sold at an average price of $53.54, for a total transaction of $1,338,500.00. Following the completion of the sale, the chief executive officer now directly owns 282,054 shares in the company, valued at approximately $15,101,171.16. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 420,610 shares of company stock worth $19,288,666 over the last ninety days. Company insiders own 29.40% of the company’s stock.

Institutional Trading of Janux Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Summit Securities Group LLC acquired a new position in shares of Janux Therapeutics during the 2nd quarter worth about $29,000. Amalgamated Bank boosted its holdings in Janux Therapeutics by 61.1% in the second quarter. Amalgamated Bank now owns 970 shares of the company’s stock valued at $41,000 after purchasing an additional 368 shares in the last quarter. Plato Investment Management Ltd acquired a new position in Janux Therapeutics in the second quarter valued at approximately $42,000. Mirae Asset Global Investments Co. Ltd. increased its stake in Janux Therapeutics by 21.9% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,887 shares of the company’s stock valued at $87,000 after purchasing an additional 339 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in Janux Therapeutics during the second quarter worth approximately $151,000. 75.39% of the stock is currently owned by institutional investors and hedge funds.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.